Boult Wade Tennant
Bulletins » The art of the possible – UKIPO publishes its AI patent guidelines.

The fading of summer is often one of those times to finish off all of those tricky projects that have built up. This is always a never-ending race as just as one thing is signed off external events find something new for you to do. In this case the UK Intellectual Property Office (UKIPO) has decided to mark the end of the summer with the publication of its long-trailed AI patentability guidelines.

Originally announced as part of the conclusion to the UKIPO’s first AI and intellectual property consultation that ran from September 2020 to March 2021 – which itself led to further work (discussed in previous bulletins) by the UKIPO exploring the appetite for changes to UK patent and copyright law around AI innovation.

Whilst, in respect of patents at least, changes to the law seem to be off the cards for now, the UK government is still keen to “unleash the power of AI” and these new Guidelines very much seem to focus on what is possible in terms of AI patents.

Meet the new approach
As with the European Patent Office before them the UKIPO is keen to emphasise that in principle AI innovation is dealt with in exactly the same way as any other computational/mathematical method or system. Many of the cases cited in the new Guidelines will be familiar to those of us who handle what are traditionally called “computer implemented inventions (CII)” at the UKIPO.

As always at the UKIPO the key consideration as to whether a CII is patentable remains “what is the technical contribution” (and is it really technical in nature). Also, as always, those not familiar with the rather particular way the patent world uses the word “technical” will, perhaps, be a little bemused at some of the outcomes.

Nevertheless, the Guidelines provide a nice discussion of some of the leading case law and, more importantly, do not shy away from tackling some of the more thorny issues around AI patentability. These include the patentability of training processes, training data (and associated processes) and even “core AI” – along with some brief discussion around what training data you may (or may not) need to disclose in an AI patent application.

The issues are addressed using some recent AI decisions where possible along with (non-binding) example “scenarios” of what (potentially) is and what is not patentable with reference to the more established non-AI case law.

A view ahead
Whilst the overall approach to AI patentability set out in the Guidelines is very much using the “old” CII system there are still some interesting, and perhaps surprising, directions hinted at – which may make for some interesting future cases. We intend to take a deeper dive into some of these in upcoming bulletins.

In any case these new Guidelines provide a good overview of what the UKIPO practice is (and to some degree how it got there) and demonstrate the wide range of possibilities for protection of AI innovation in the UK patent system. The art of the possible may, after all, provide applicants with valuable protection for their AI innovation.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications